書籍詳細

上部消化管PART I●食道疾患

P.13 掲載の参考文献

• 1) Berger K, NcCallum RW: Nifedipine in the treatment of achalasia. Ann lntern. Med 96: 61-62, 1982

• 2) Triadafilopoulos G, Aaronson M, Sackel S et al: Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo. Dig Dis Sci 36: 260-267, 1991
  pubmed

• 3) Bassotti G, Annese V: Review article: pharmacological options in achalasia・Aliment Pharmacol Ther 13: 1391-1396, 1999

P.15 掲載の参考文献

• 1) Pasricha PJ, Ravich WJ, Kalloo AN: Effects of intrasphincteric botulinum toxin on the lower esophageal sphincter in piglets. Gastroenterology 105: 1045-1049, 1993
  pubmed

• 2) Pasricha PJ, Ravich WJ, Hendrix TR et al: Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial. Ann lntern Med 121: 590-591, 1994
  pubmed

• 3) Vaezi MF, Richter JE: Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol 27: 21-35, 1998
  pubmed

P.17 掲載の参考文献

• 1) Pasricha PJ, Rai R, Ravich WJ et al: Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 110: 1410-1415, 1996
  pubmed

• 2) Panaccione R, Gregor JC, Reynolds RP et al: Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis. Gastrointest Endosc 50: 492-498, 1999
  pubmed

• 3) Annese V, Bassotti G, Coccia G et al: A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut 46: 597-600, 2000
  pubmed

P.19 掲載の参考文献

• 1) Dent J, Yeomans ND, Mackinnon M et al: Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 35: 590-598, 1994

• 2) Zeitoun P, Barbier P, Cayphas JP et al: Comparison of two dosage regimen of reflux esophagitis-10mg once daily and 20mg weekends-as prophylaxis against reccurence of reflux esophagitis. Hepatogastroenterology 36: 279-280, 1989

• 3) Crobach LF, Jansen JB, Lamers CB: Effect of intermittent weekend therapy with omeprazole on basal and bombesin-and pentagastrin-stimulated gastric acid and serum gastrin. Scand J Gastroenterol 23: 407-412, 1988
  pubmed

P.21 掲載の参考文献

• 1) Havelund T, Laursen LS, Skoubo-Kristensen E et al: Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J 296: 89-92, 1988

• 2) Hetzel DJ, Dent J, Reed WD et al: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903-912, 1988

• 3) Lundell L, Westin IH, Sandmark S et al: Omeprazole or high dose ranitidine in the treatment of patients with reflux oesophagitis not responding to standard doses of H2-receptor antagonists. Gastroenterology 96: A310, 1989

P.23 掲載の参考文献

• 1) Jones R, Crouch SL: Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 13: 413-419, 1999
  pubmed

• 2) Hatlebakk JG, Berstad A: Lansoprazole 15 and 30mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 11: 365-372, 1997

P.26 掲載の参考文献

• 1) Bate CM, Keeling PW, O'Morain C et al: Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 31: 968-972, 1990
  pubmed

• 2) Klinkenberg-Knol EC, Jansen JMB, Festen HPM et al: Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. Lancet 1: 349-351, 1987

• 3) Sandmark S, Carlsson R, Fausa O et al: Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 23: 625-632, 1988
  pubmed

P.29 掲載の参考文献

• 1) Vigneri S, Termini R, Leandro G et al: A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106-1110, 1995

• 2) Bell NJV, Hunt RH: Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33: 118-124, 1992

P.31 掲載の参考文献

• 1) Hetzel DJ, Dent J, Reed WD et al: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903-912, 1988

P.33 掲載の参考文献

• 1) Robinson M, Sahba B, Avner D et al: A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 9: 25-31, 1995
  pubmed

P.35 掲載の参考文献

• 1) Orr WC, Finn A, Wilson T et al: Esophageal acid contact time and heartburn in acute treatment with ranitidine and metoclopramide. Am J Gastroenterol 85: 697-700, 1990
  pubmed

• 2) Chiba N, De Gara CJ, Wilkinson JM et al: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112: 1798-1810, 1997
  pubmed

P.37 掲載の参考文献

• 1) Orr WC, Robinson MG, Humphries TJ et al: Dose-response effect of famotidine on patterns of gastroesophageal reflux. Aliment pharmacol Ther 2: 229-235, 1988
  pubmed

• 2) Robinsen M, Decktor DL, Stone RC et al: Famotidine (20mg) b. d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Aliment pharmacol Ther 5: 631-643, 1991

• 3) Wesdorp IC: Famotidine in gastroesophageal reflux disease (GERD) . Hepatogastroenterology 39 (suppl 1): 24-26, 1992

P.39 掲載の参考文献

• 1) Rowinsky EK, Citardi MJ, Noe DA et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733, 1993
  pubmed

• 2) Bhalla KN, Kumar GN, Walle T et al: Phase I and pharmacokinetic trial of a 3-hour infusion of Taxol, Cisplatin plus 5-fluorouracil in advanced solid tumors. Proc Am Soc Clin Oncol 13: 165, 1994

P.41 掲載の参考文献

• 1) Lokich J, Anderson N, Moore C et al: Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas. Eur J Cancer 34: 664-667, 1998
  pubmed

• 2) 根来俊一: 進行非小細胞肺癌の治療. 癌と化学療法 25: 1671-1679, 1998
  Medical*Online

• 3) 上岡 博: 肺癌に対する新しい併用療法. 癌と化学療法27: 356-361, 2000

P.43 掲載の参考文献

• 1) Lippman SM, Parkinson DR, Itri LM et al: 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer lnst 84: 235 241, 1992

• 2) LipPman SM, Kavanagh JJ, Paredes-Espinoza M et al: 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer lnst 84: 241-245, 1992

上部消化管PART II●胃・十二指腸疾患

P.48 掲載の参考文献

• 1) 竹本忠良ほか: AGMLの臨床および研究の展望. 消化器内視鏡2: 759-765, 1990

• 2) 木村 健ほか: 急性胃粘膜病変の診断. 臨床消化器内科3: 1397-1406, 1988

• 3) 竹本忠良ほか: 急性胃炎, 慢性胃炎の急性増悪期に対するrebamipideの用量設定試験-二重盲検比較試験による2用量の比較検討-. 臨床成人病 23: 1163-1190, 1993

• 4) 小林絢三ほか: 急性胃炎, 慢性胃炎の急性増悪期に対するrebamipideの臨床評価-二重盲検法による服用時期の比較検討-. 臨床成人病 23: 1003-1028, 1993

P.51 掲載の参考文献

• 1) Konturek SJ, Brzozowski T, Mach T et al: Importance of an acid milieu in the sucralfate-induced gastroprotection against ethanol damage. Scand J Gastroenterol 24: 807-812, 1989
  pubmed

• 2) Konturek JW, Hengst K, Konturek SJ et al: Physiological role of cholecystokinin in gastroprotection in humans. Am J Gastroenterol 93: 2385-2390, 1998
  pubmed

P.53 掲載の参考文献

• 1) Alderman BM, Cook GA, Familari M et al: Resistance to apoptosis is a mechanism of adaptation of rat stomach to aspirin. Am J Physiol Gastrointest Liver Physiol 278: 839-846, 2000

• 2) Donnelly MT, Goddard AF, Filipowicz B et al: Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 14: 529-534, 2000
  pubmed

• 3) Lanza FL, Rack MF, Li Z et al: Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs aspirin In healthy postmenopausal women[In Process Citation]. Aliment Pharmacol Ther 14: 1663-1670, 2000

• 4) Levy DJ: Images in clinical medicine. An aspirin tablet and a gastric ulcer. N Engl J Med 343: 863, 2000

• 5) Mitobe Y, Hiraishi H, Sasai T et al: The effects of aspirin on antioxidant defences of cultured rat gastric mucosal cells. Aliment Pharmacol Ther 14 (suppl 1): 10-17, 2000

• 6) Mourad FH, Khuri M, Shouaib F et al: Protective effect of the nitric oxide donor molsidomine on indomethacin and aspirin-induced gastric injury in rats. Eur J Gastroenterol Hepatol 12: 81-84, 2000
  pubmed

• 7) Ranta-Knuuttila T, Mustonen H, Kivilaakso E: Topical prostaglandin E2 protects isolated gastric mucosa against acidified taurocholate-, but not ethanol-or aspirin-induced injury. Dig Dis Sci 45: 99-104, 2000
  pubmed

• 8) Sorensen HT, Mellemkjaer L, Blot WJ et al: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 95: 2218-2224, 2000
  pubmed

• 9) Sugimoto N, Yoshida N, Yoshikawa T et al: Effect of vitamin E on aspirin-induced gastric mucosal injury in rats. Dig Dis Sci 45: 599-605, 2000
  pubmed

P.55 掲載の参考文献

• 1) Fuji Y, Matsura T, Kai M et al: Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells[In Process Citation]. Jpn J Pharmacol 84: 63-70, 2000

• 2) Fujii Y, Matsura T, Kai M et al: Mitochondrial cytochrome c release and caspase-3-like protease activation during indomethacin-induced apoptosis in rat gastric mucosal cells. Proc Soc Exp Biol Med 224: 102-108, 2000
  pubmed

• 3) Lempinen M, Inkinen K, Wolff H et al: Matrix metalloproteinases 2 and 9 in indomethacin-induced rat gastric ulcer. Eur Surg Res 32: 169-176, 2000
  pubmed

• 4) Mourad FH, Khuri M, Shouaib F et al: Protective effect of the nitric oxide donor molsidomine on indomethacin and aspirin-induced gastric injury in rats. Eur J Gastroenterol Hepatol l2 : 81-84, 2000

• 5) Podvigina TT, Bogdanov AI, Filaretova LP: [The role of glucocorticoids in healing of indomethacin-induced lesions in the rat gastric mucosa]. Ross Fiziol Zh I M Sechenova 86: 720-727, 2000

• 6) Slomiany BL, Slomiany A: Role of endothelin-converting enzyme-1 in the suppression of constitutive nitric oxide synthase in rat gastric mucosal injury by indomethacin. [In Process Citation]. Scand J Gastroenterol 35: 1131-1136, 2000

P.57 掲載の参考文献

• 1) Hahn BA, Kirchdoerfer LJ, Fullerton S et al: Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 11 : 547-552, 1997
  pubmed

• 2) Wiklund IK, Junghard O, Grace E et al: Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD) . Eur J Surg Suppl (583): 41-49, 1998
  pubmed

• 3) Wong E, Guyatt GH, Cook DJ et al: Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur J Surg Suppl (583): 50-56, 1998
  pubmed

• 4) Talley NJ, Verlinden M, Jones M: Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 94: 2390-2397, 1999
  pubmed

• 5) Drossman DA, Patrick DL, Whitehead WE et al: Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire・Am J Gastroenterol 95: 999-1007, 2000

P.59 掲載の参考文献

• 1) Talley NJ, Axon A, Bytzer P et al: Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 13: 1135-1148, 1999
  pubmed

P.61 掲載の参考文献

• 1) Veldhuyzen van Zanten SJO, Cleary C, Talley NJ et al: Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 91: 660-673, 1996

P.63 掲載の参考文献

• 1) Verdu EF, Armstrong D, Idstrom JP et al: Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and Helicobacter pylori-associated gastritis. Scand J Gastroenterol 31: 1151-1156, 1996
  pubmed

• 2) Junghard O, Lauritsen K, Talley NJ et al: Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg Suppl 1: 106-111, 1998

• 3) Talley NJ: A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 106: 1174-1183, 1994
  pubmed

P.65 掲載の参考文献

• 1) Talley NJ, Hunt RH: What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 113 (suppl): S67-S77, 1997

• 2) Gilvarry J, Buckley MJ, Beattie S et al: Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 32: 535-540, 1997
  pubmed

P.67 掲載の参考文献

• 1) Walt RP, Gomes M de FA, Word EC et al: Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 287: 12-14, 1983

• 2) Gustavsson S, Adami HO, L??f L et al: Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. Lancet 2: 124-125, 1983

• 3) Scandinavian Multicentre Study: Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. Scand J Gastroenterol 19: 882-884, 1984

P.70 掲載の参考文献

• 1) Classen M, Dammann HG, Domschke W et al: Abheilungsraten nach Omeprazol-und Ranitidin- Behandlung des Ulcus ventriculi: ergebnisse einer deutchen Multizenterstudie. Dtsch Med Wochenschr 110: 628-633, 1985

• 2) Lanzon-Miller S, Pounder RE, Hamilton MR et al: Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1 : 239-251, 1987
  pubmed

P.73 掲載の参考文献

• 1) Walan A, Bianchi-Porro G, Hentschel E et al: Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 22: 397-405, 1987
  pubmed

• 2) Penston JG: Maintenance treatment versus no maintenance treatment in patients with duodenal ulcer disease. Scand J Gastroenterol 25 (suppl177): 42-51, 1990

• 3) Jensen DM, You S, Machicado GA et al: Long-term recurrence rates of peptic ulceration and rebleeding with H2 maintenance, surgery or no maintenance therapy. Gastroenterology 96: A239 (abstract), 1989

P.75 掲載の参考文献

• 1) Fries JF: NSAID gastropathy: Epidemiology. J Musculoskeletal Med 8: 21-28, 1991

• 2) Kobayashi K, Mizushima Y, Yanagawa A et al: Prophylactic effects ranitidine, a H2 receptor antagonist, on gastric and duodenal lesions induced by nonsteroidal anti-inflammatory agents. J Adult Dis 20: 253-264, 1990

• 3) Naito Y, Yoshikawa T, Tanigawa T et al: Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18: 117-123, 1995
  pubmed

P.77 掲載の参考文献

• 1) Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899, 1999
  pubmed

• 2) Schoen RT, Vender RJ: Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 86: 449-458, 1989
  pubmed

• 3) Taha AS, Hudson N, Hawkey CJ et al: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334: 1435-1439, 1996
  pubmed

• 4) Walan A, Bader JP, Classen M et al: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320: 69-75, 1989
  pubmed

P.79 掲載の参考文献

• 1) McCarthy DM: Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology 96 (suppl): 662-674, 1989

• 2) Ekstrom P, Carling L, Wetterhus S et al: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 31: 753-758, 1996
  pubmed

P.81 掲載の参考文献

• 1) Giercksky KE, Huseby G, Rugstad HE: Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl 163: 3-8, 1989
  pubmed

• 2) Walan A, Bader JP, Classen M et al: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320: 69-75, 1989
  pubmed

P.83 掲載の参考文献

• 1) Graham DY, Agrawal NM, Roth SH: Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2: 1277-1280, 1988
  pubmed

• 2) Aabakken L, Bjornbeth BA, Weberg R et al: NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid-and distal duodenum? Aliment. Pharmachol Ther 4: 295-303, 1990
  pubmed

• 3) Simon TJ, Berger ML, Hoover ME et al: A dose-ranging study of famotidine in prevention of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs (NSAIDs): results of a U. S. multicenter trial. Am J Gastroenterol 89: A 1644 (abstract), 1994

P.85 掲載の参考文献

• 1) Hawkey CJ, Tulassay Z, Szczepanski L et al: Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 352: 1016-1021, 1998
  pubmed

P.87 掲載の参考文献

• 1) Hosking SW, Ling TK, Chung SC et al: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 343: 508-510, 1994
  pubmed

P.89 掲載の参考文献

• 1) Hawkey CJ, Jeffrey AK, Szczepanski L et al: A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non steroidal anti-inflammatory drugs. N Engl J Med 338: 727-734, 1998

• 2) Chan FKL, Sung JJY, Chung SCS et al: Randomised eradication of H. pylory before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350: 975-979, 1997

P.91 掲載の参考文献

• 1) Fries JF: NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisa1. J Rheumatol Suppl 28: 6-10, 1991
  pubmed

• 2) Walt RP: Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 327: 1575-1580, 1992
  pubmed

• 3) Hawkey CJ, Karrasch JA, Szczepanski L et al: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338: 727-734, 1998

P.94 掲載の参考文献

• 1) Bhargava DK, Dasarathy S, Atmakuri SP et al: Comparative efficacy of emergency endoscopic sclerotherapy for active variceal bleeding due to cirrhosis of the liver, non-cirrhotic portal fibrosis and extrahepatic portal venous obstruction. J Gastroenterol Hepatol 5: 432-437, 1990
  pubmed

• 2) Terblanche J, Northover JM, Bornman P et al: A prospective evaluation of injection sclerotherapy in the treatment of acute bleeding from esophageal varices. Surgery 85: 239-245, 1979
  pubmed

• 3) Bhargava DK, Singh B, Dogra R et al: Prospective randomized comparison of sodium tetradecyl sulfate and polidocanol as variceal sclerosing agents. Am J Gastroenterol 87: 182-186, 1992
  pubmed

P.98 掲載の参考文献

• 1) Walan A, Bianchi-Porro G, Hentschel E et al: Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 22: 397-405, 1987
  pubmed

• 2) Jensen DM, Machicado GA, Kovacs TO et al: CURE Hematostasis Research Group. Long-term recurrence rates of peptic ulceration and rebleeding with H2 maintenance, surgery or no maintenance therapy. Gastroentelogy 96 (suppl 1): A239, 1989 (Abstr)

• 3) Sonnenberg A, Olson CA, Zhang J: The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 94: 950-954, 1999

P.101 掲載の参考文献

• 1) Graham DY, Hepps KS, Ramirez FC et al: Treatment of Helicobacter pylori: : reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28: 939-942, 1993
  pubmed

• 2) Santander C, Gravalos RG, Gomez-Cedenilla A et al: Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: Prospective nonrandomized trial on 125 patients. Am J Gastroenterol 91: 1549-1552, 1996
  pubmed

• 3) Labenz J, B?rsch G: Role of Helicobacter Pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 55: 19-23, 1994

• 4) Rokkas T, Karameris A, Mavrogeogis A et al: Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 41: 1-4, 1995
  pubmed

• 5) Jaspersen D, Koerner T, Schorr W et al: Helicobacter pylori eradication reduces the rate of rebleeding in ulcer haemorrhage. Gastrointest Endosc 41: 5-7, 1995
  pubmed

• 6) Ponell KU, Bell GD, Bolton GH et al: Helicobacter pylori eradication in patients with peptic ulcer disease: Clinical consequences and financial implications. Quat J Med 87: 283-290, 1994

P.103 掲載の参考文献

• 1) Walt RP, Cottrell J, Mann SG et al: Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 340: 1058-1062, 1992
  pubmed

• 2) Collins R, Langman M: Treatment with histamine H2 antagonists in acute upPer gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 313: 660-666, 1985
  pubmed

• 3) Daneshmend TK, Hawkey CJ, Langman MJ et al: Omeprazole versus placedo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 304: 143-147, 1992

P.105 掲載の参考文献

• 1) Chiba N, Rao BV, Rademaker JW et al: Meta- analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 87: 1716-1727, 1992
  pubmed

• 2) Treiber G: The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 91: 246-257, 1996
  pubmed

P.107 掲載の参考文献

• 1) Rauws EA, Tytgat GN: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335: 1233-1235, 1990
  pubmed

• 2) Graham DY, Lew GM, Klein PD et al: Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann lntern Med 116: 705-708, 1992
  pubmed

• 3) Rabeneck L, Ransohoff DF: Is Helicobacter pylori a cause of duodenal ulcer？ A methodologic critique of current evidence. Am J Med 91: 566-572, 1991
  pubmed

P.109 掲載の参考文献

• 1) George LL, Borody TJ, Andrews P et al: Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 153: 145-149, 1990
  pubmed

• 2) Graham DY, Lew GM, Malaty HM et al: Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102: 493-496, 1992
  pubmed

P.111 掲載の参考文献

• 1) Van der Hulst RW, Tytgat GN: Helicobacter pylori and peptic ulcer disease. Scand J Gastroenterol Supple 220: 10-18, 1996

• 2) Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 110: 1244-1252, 1996
  pubmed

P.113 掲載の参考文献

• 1) Goh KL, Boonyapisit S, Lai KH et al: Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: arandomized double-blind, placebo-controlled study. J Gastroenterol Hepatol 10: 92-97, 1995

• 2) Santander C, Gravalos RG, Gomez-Cedenilla A et al: Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 91: 1549-1552, 1996
  pubmed

P.115 掲載の参考文献

• 1) Coghlan JG, Gilligan D, Humphries H et al: Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet 2: 1109-1111, 1987
  pubmed

• 2) Marshall BJ, Goodwin CS, Warren JR et al: Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2: 1437-1442, 1988
  pubmed

• 3) Rauws EA, Tytgat GN: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335: 1233-1235, 1990
  pubmed

P.117 掲載の参考文献

• 1) Rauws EA, Langenberg W, Houthoff HJ et al: Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 94: 33-40, 1988
  pubmed

• 2) Hosking SW, Ling TK, Chung SC et al: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 343: 508-510, 1994
  pubmed

P.119 掲載の参考文献

• 1) Smyth JF, Coleman RE, Nicolson M et al: Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 303: 1423-1426, 1991
  pubmed

• 2) Pater JL, Lofsters WS, Zee B et al: The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8: 181-185, 1997

• 3) Osoba D, Warr DG, Fitch MI et al: Guidelines for the optimal management of chemotherapy-induced nausea and vomiting a consensus. Can J Oncol 5: 381-400, 1995
  pubmed

P.121 掲載の参考文献

• 1) Andrews PL, Rapeport WG, Sanger GJ: Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 9: 334-341, 1988
  pubmed

• 2) 古江 尚: 癌化学療法における悪心・嘔吐対策.癌治療と宿主4: 75-85, 1992

• 3) 住永雅司, 古江 尚, 太田和雄ほか: 抗悪性腫瘍剤による悪心・嘔吐に対するGranisetron経口剤の臨床評価-至適用量の検討-. 癌と化学療法 20: 1203-1210, 1993
  Medical*Online

P.123 掲載の参考文献

• 1) Hesketh PJ, Gralla RJ, Webb RT et al: Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis. J Clin Oncol 17: 338-343, 1999
  pubmed

• 2) Yamakuni H, Sawai H, Maeda Y et al: Probable involvement of the 5-hydroxytryptamine (4) receptor in methotrexate-induced delayed emesis in dogs. J Pharmacol Exp Ther 292: 1002-1007, 2000

P.125 掲載の参考文献

• 1) 馬場秀夫, 鴻江俊治, 遠藤和也ほか: 消化器癌治療のState of the Art. 癌と化学療法 27: 1233-1246, 2000
  Medical*Online

• 2) 小西敏郎, 出月康夫, 渡辺 弘ほか: 胃癌・大腸癌の術後補助療法におけるUFT単独投与とOK-432 併用投与の比較. 癌と化学療法25: 887-900, 2000

P.127 掲載の参考文献

• 1) Silverstein FE, Graham DY, Senior JR et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial Ann lntern Med 123: 241-249, 1995
  pubmed

• 2) Chan CC, Boyce S, Brideau C et al: Rofecoxib 〔Vioxx, MK-0966, 4- (4'-methylsulfonyl-phenyl) -3-phenyl-2- (5H) -furanone〕: a potent and orally active cyclooxygenase-2 inhibitor. pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551-560, 1999

• 3) Mohammed S, Croom DW 2nd: Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor. N Engl J Med 340: 2005-2006, 1999
  pubmed

P.128 掲載の参考文献

• 1) Gisbert JP, Gisbert JL, Marcos S et al: Seven-day ‘rescue': therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs ranitidine bismuth citrate, tetracycline and metronidazole. Aliment pharmacol Ther 13: 1311-1316, 1999

• 2) Gomollon F, Ducons JA, Ferrero M et al: Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 4: 222-225, 1999
  pubmed

P.131 掲載の参考文献

• 1) Borsch G, Wegener M, Mai U et al: Efficiency of oral triple therapy to eradicate Campylobacter pylori. In: Gastroduodenal pathology and Campylobacter pylori. ed by Megraud F, Lamouliatte H Amsterdam, Elsevier 1989, pp 595-598

• 2) Labenz J, Gyenes E, Ruhl GH et al: Efficiency of oral triple therapy (BSS/metronidazole/tetracycline) to eradicate HP in DU disease. Ir J Med Sci 161: 90, 1992

• 3) Byerdorffer E, Mannes GA, Sommer A et al: High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 4: 697-702, 1992

P.133 掲載の参考文献

• 1) Bazzoli F, Zagari RM, Fossi S et al: Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 6: 773-777, 1994

• 2) Bell GD, Powell KU, Burridge SM et al: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 9: 41-46, 1995
  pubmed

P.135 掲載の参考文献

• 1) Laine L, Frantz JE, Baker A et al: A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 11 : 913-917, 1997

• 2) Miyaji H, Azuma T, Ito S et al: Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 11 : 1131-1136, 1997
  pubmed

P.137 掲載の参考文献

• 1) Lind T, Veldhuyzen van Zanten SV, Unge P et al: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 Study. Helicobacter 1 : 138-144, 1996

• 2) Hentschel E, Brandstatter G, Dragosics B et al: Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 328: 308-312, 1993
  pubmed

P.138 掲載の参考文献

• 1) Grigoriev PY, Zoseeva OV, Yokovenko AV et al: Ranitidine antimicrobial therapy vs omeprazole antimicrobial therapy for Helicobacter pylori associated peptic ulcer. Am J Gastroenterol 89: 1392, 1994

• 2) Catalano F, Privitera U, Branciforte G et al: Omeprazole plus clarithromycin: efficacy of two treatment regimens on Helicobacter pylori positive duodenal ulcer. Ann Exp Clin Med 34: 93-97, 1995

P.141 掲載の参考文献

• 1) McLaren A, Donnelly C, McDowell S et al: The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. Helicobacter 2: 21- 26, 1997

P.143 掲載の参考文献

• 1) Furuta T, Ohashi K, Kosuge K et al: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65: 552-561, 1999
  pubmed

• 2) Termanini B, Gibril F, Sutliff VE et al: Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104: 422-430, 1998

下部消化管●小腸・大腸疾患

P.147 掲載の参考文献

• 1) van Hees PA, Bakker JH, van Tongeren JH: Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 21: 632-635, 1980
  pubmed

• 2) Schroder H, Campbell DE: Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 13: 539-551, 1972
  pubmed

• 3) Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629, 1987
  pubmed

P.149 掲載の参考文献

• 1) Lofberg R, Thomsen O, Langholtz E et al: Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 8: 623-629, 1994

• 2) Rutgeerts P: Budesonide enemas for topical therapy of ulcerative colitis. Can J Gastroenterol 4: 415-416, 1990

• 3) Porro GB, Prantera C, Campieri M et al: Comparative trial of methyl prednisolone and budesonide enemas in active distal ulcerative colitis. J Gastroenterol Hepatol 6: 125-130, 1994

• 4) The Danish Budesonide Study Group: Budesonide enema in distal ulcerative colitis: a randomized dose-response trial with prednisolone enama as positive control. J Gastroenterol 26: 1225-1230, 1991

P.151 掲載の参考文献

• 1) Kosaka T, Sawada K, Ohnishi K et al: Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Internal Medicine 38: 102-111, 1999
  pubmed

• 2) 下山 孝, 澤田康史, 大西国夫ほか: 潰瘍性大腸炎 の白血球系細胞吸着・除去療法. 日内会誌88: 724-730, 1999

• 3) 澤田康史, 大西国夫, 江藤明盛ほか: 潰瘍性大腸炎に対する白血球系細胞除去療法. 日本アフェレシス学会雑誌18: 99-104, 1999

P.153 掲載の参考文献

• 1) 棟方昭博, 村田有志, 鈴木和夫ほか: 潰瘍性大腸炎での免疫抑制剤投与例の検討. 厚生省特定疾患難治性炎症性腸管障害調査研究班, 平成4年度研究報告書, 1993, pp 94-97

• 2) Dubinsky MC, Lamothe S, Yang HY et al: Pharmacogenomics and metabolite measurement for 6-Mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705-713, 2000
  pubmed

P.156 掲載の参考文献

• 1) Lichtiger S, Present DH: Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 336: 16-19, 1990
  pubmed

• 2) Kozarek R, Bedard C, Patterson D et al (Pacific Northwest Gastroenterology Society): Cyclosporin use in the precolectomy chronic ulcerative colitis patient: A community experience and its relationship to prospective and controlled clinical trials. Am J Gastroenterol 90: 2093-2096, 1995

• 3) Sandborn WJ: A clinical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1 : 48-63, 1995

• 4) Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 91: 423-433, 1996
  pubmed

P.159 掲載の参考文献

• 1) Jick H, Walker AM: Cigarette smoking and ulcerative colitis. N Engl J Med 308: 261-263, 1983
  pubmed

• 2) Haynes RB: Incorporating allocation concealment and blinding in randomized controlled trials. ACP Journal Club 132: A-13, 2000

P.161 掲載の参考文献

• 1) Dissanayake AS, Truelove SC: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 14: 923-926, 1973
  pubmed

• 2) Ewe K Herfarth C, Malchow H et al: Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 42: 224-232, 1989
  pubmed

• 3) Messori A, Brignola C, Trallori G et al: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89: 692-698, 1994
  pubmed

P.163 掲載の参考文献

• 1) 樋渡信夫: クローン病治療指針改訂案. 厚生省特定疾患難治性炎症性腸管障害調査研究班平成9年度研究報告書 (班長: 下山 孝), 1998, pp 104-107

• 2) Summers RW, Switz DM, Sessions JT Jr et al: National Cooperative Crohn's disease Study: results of drug treatment. Gastroenterology 77: 847-869, 1979
  pubmed

• 3) Matsueda K, Shoda R, Takazoe M et al: Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn's disease: Japanese cooperative Crohn's disease study. J Gastroenterol 30: 91-94, 1995
  pubmed

P.165 掲載の参考文献

• 1) Femandez-Banares F, Bertran X, Esteve-Comas M et al: Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 91: 2498-2499, 1996

• 2) Pearson DC, May GR Fick GH et al: Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123: 132-142, 1995
  pubmed

P.167 掲載の参考文献

• 1) Jewell D, Lennard-Jones JE: Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 6: 499-505, 1994

• 2) Kozarek RA, Patterson DJ, Gelfand MD et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann lntern Med 110: 353-356, 1989
  pubmed

P.169 掲載の参考文献

• 1) van Dullemen HM, van Deventer SJ, Hommes DW et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109: 129-135, 1995
  pubmed

• 2) Targan SR, Hanauer SB, van Denventer SJ et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337: 1029-1035, 1997

P.171 掲載の参考文献

• 1) Shanahan F: Anti-TNF therapy for Crohn's disease: a perspective. Inflammatory Bowel Disease 6: 137-139, 2000
  pubmed

P.173 掲載の参考文献

• 1) Schreiber S, Heinig T, Thiele HG et al: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108: 1434-1444, 1995
  pubmed

• 2) Smeets TJ, Kraan MC, Versendaal J et al: Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol 26: 2089-2093, 1999
  pubmed

• 3) McHutchison JG, Giannelli G, Nyberg L et al: A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J Interferon Cytokine Res 19: 1265-1270, 1999

P.175 掲載の参考文献

• 1) 里見匡迫, 澤田康史, 福田能啓ほか: 炎症性腸疾患の治療法の変遷. 消化器外科19: 1127-1136, 1996

• 2) 福田能啓, 平川博之: 炎症性腸疾患に対する新しい栄養療法. 消化器科15: 189-197, 1991

P.178 掲載の参考文献

• 1) Lorenz-Meyer H, Bauer P, Nicolay C et al: Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Scand J Gastroentrol 31: 778-785, 1996

• 2) Matsueda K, Shoda R, Takazoe M et al: Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn's disease: Japanese cooperative Crohn's disease study. J Gastroenterol 30 (suppl VIII): 91-94, 1995

P.181 掲載の参考文献

• 1) Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136: 5-28, 1993

• 2) European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-1325, 1995

• 3) Hassard PV, Vasiliauskas EA, Kam LY et al: Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 6: 16-20, 2000
  pubmed

• 4) Fellermann K, Steffen M, Stein J et al: Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14: 171-176, 2000
  pubmed

P.183 掲載の参考文献

• 1) Sandbom WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 92: 876-879, 1997

• 2) Lowry PW, Weaver AL, Tremaine WJ et al: Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment -refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 5: 239-245. 1999
  pubmed

• 3) 日比紀文, 船越信介: クローン病の治療. Frontiers in Gastroenterology 5: 22-28, 2000

P.189 掲載の参考文献

• 1) 五島瑳智子, 徐慶一朗, 河喜多竜祥ほか: 最小発育阻止濃度 (MIC) 測定法再改訂について. 29: 76-79, 1981.

P.191 掲載の参考文献

• 1) 香坂隆夫, 田河 学, 鈴木輝明ほか: EHEC感染症における抗菌剤の使用上の問題点-この古くて新しい問題提起. 日本臨床 55: 706-714, 1997

• 2) 竹田美文: 一次, 二次医療機関のための腸管出血性大腸菌 (O157等) 感染症治療の手引き改訂版. 日本医師会雑誌 118: 1085-11092, 1997

• 3) 相楽裕子: O157の感染ルートは解明されたのか. 治療法にconsensusは得られたのか. 内科 82: 541-544, 1998

P.193 掲載の参考文献

• 1) 竹田多恵, 吉野健一, 松田枝里子ほか: Vero毒素吸着剤の開発研究の動向. 日本臨床 55: 751-757, 1997
  Medical*Online

• 2) 香坂隆夫, 田川 学, 鈴木輝明ほか: EHEC感染症における抗生剤の使用上の問題. 日本臨床 55: 706-714, 1997

P.195 掲載の参考文献

• 1) Rao PM, Rhea JT, Novelline RA et al: Helical CT technique for diagnosis of appendicitis: prospective evaluation of a focused appendix CT examination. Radiology 202: 139-144, 1997
  pubmed

• 2) Rao PM, Rhea JT, Novelline RA et al: Helical CT combined with contrast material administered only through the colon for imaging of suspected appendicitis. AJR 169: 1275-1280, 1997
  pubmed

P.198 掲載の参考文献

• 1) Anonymous: The advanced colorectal cancer meta-analysis project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992

• 2) Machover D, Goldschmidt E, Chollet P et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685-696, 1986
  pubmed

• 3) Scheithauer W, Kornek G, Marczell A et al: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 15: 908-914, 1997
  pubmed

P.201 掲載の参考文献

• 1) Miller AB, Hoogstraten B, Staquet M et al: Reponing results of cancer treatment. Cancer 47: 207-214, 1981

• 2) Mantel H, Haenzel W: Statsitical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer lnst 22: 719-748, 1959

• 3) Cox DR: The Analysis of Binary Data, Methuen, London, United Kingdom, 1970

• 4) Peto R, Pike MC, Armitage P et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39, 1977
  pubmed

P.203 掲載の参考文献

• 1) Pazdur R, Douillard J-Y, Skillings JR et al: Multicenter phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc ASCO 18: 263a, 1999

• 2) Carmichael J, Popdiela T, Radstone D et al: Randomized comparative study of ORZEL?〔oral uracil/tegafur (UFT)〕plus leucovorin versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Proc ASCO 18: 264a, 1999

P.205 掲載の参考文献

• 1) Kusunoki M, Yanagi H, Kotera H et al: Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinoma with P53 overexpression. 1nt J Oncol 13: 653-657, 1998

• 2) Fujii S, Fukushima M, Shimamoto Y et al: Pharmacokinetic modulation of plasma 5-fluorouracil concentration to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil. Jpn J Cancer Res 80: 509-512, 1989
  pubmed

• 3) Piedbois P, Buyse M, Rustum Y et al: (Advanced colorectal cancer meta-analysis project) modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J CIin Oncol 10 : 896-903, 1992

P.207 掲載の参考文献

• 1) Rougier P, Bugat R, Douillard JY et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997
  pubmed

• 2) Cunningham D, Glimelius B: A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 26 (suppl 5): 6-12, 1999

• 3) Van Custem E, Bilijham GH: Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Semin Oncol 26 (suppl 5): 12-20, 1999

P.209 掲載の参考文献

• 1) Wadler S, Lemberskey B, Atkins M et al: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastren Cooperative Oncology Group study. J CIin Oncol 9: 1806-1810, 1991

• 2) Makower D, Walder S: Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer. Semin Oncol 26: 663-671, 1999

• 3) Villar-Grimalt A, Candel MT, Massuti B et al: A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorecta1 cancer. Br J Cancer 80: 786-791, 1999
  pubmed

P.211 掲載の参考文献

• 1) 宮島伸宜, 山川達郎: 大腸癌に対する minimally invasive surgery の適応と成績. 日消外会誌31: 1038-1042, 1998.

• 2) 福永正氣, 木所昭夫, 射場敏明ほか: 右側結腸癌に対する腹腔鏡下手術. 消化器外科 22: 175-187, 1999

• 3) Okuda J, Tanigawa N: Colon carcinomas may be adequetely treated using laparoscopic methods. Semin Colon Rectal Surg 9: 241-245, 1998

P.213 掲載の参考文献

• 1) Thun MJ, Namboodiri MM, Heath CW Jr et al: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991
  pubmed

• 2) Sawaoka H, Kawano S, Tsuji S et al: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274: G1061-G1067, 1998
  pubmed

P.215 掲載の参考文献

• 1) Gann PH, Manson JE, Glynn RJ et al: Low-dose aspirin and incidence of colorectal tumors in a randomized tria1. J Natl Cancer lnst 85: 1220-1224, 1993

• 2) Peleg II, Maibach HT, Brown SH et al: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch lntern Med 154: 394-399, 1994
  pubmed

• 3) Rosenberg L, Palmer JR, Zauber AG et al: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence Of large-bowel cancer. J Natl Cancer lnst 83: 355-358, 1991

P.217 掲載の参考文献

• 1) Ahlquist DA, Wieand HS, Moertel CG et al: Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 269: 1262-1267, 1993
  pubmed

• 2) Lang CA, Ransohoff DF: Fecal occult blood screening for colorecta1 cancer. ls mortality reduced by chance selection for screening colonoscopy？ JAMA 271: 1011-1013, 1994

• 3) Selby JV, Friedman GD, Quesenberry CP Jr et al: A case-control study of screening sigmoidoscopy and mortality from colorecta1 cancer. N Engl J Med 326: 653-657, 1992
  pubmed

P.219 掲載の参考文献

• 1) Mandel JS, Bond JH, Bradley M et al: Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. Gastroenterology 97: 597-600, 1989
  pubmed

• 2) Ahlquist DA, Wieand HS, Moertel CG et al: Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 269: 1262-1267, 1993
  pubmed

• 3) Lang CA, Ransohoff DF: Fecal occult blood screening for colorecta1 cancer. ls mortality reduced by chance selection for screening colonoscopy？ JAMA 271: 1011-1013, 1994

P.221 掲載の参考文献

• 1) Mandel JS, Bond JH, Church TR et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371, 1993
  pubmed

• 2) Kronborg O, Fenger C, Olsen J et al: Randomised study of screening for colorectal cancer with faecal -occult-blood test. Lancet 348: 1467-1471, 1996
  pubmed

• 3) Hardcastle JD, Chamberlain JO, Robinson MH et al: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477, 1996
  pubmed

P.223 掲載の参考文献

• 1) Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83-87, 1983

• 2) Giardiello FM, Hamilton SR, Krush AJ et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993
  pubmed

• 3) Rao CV, Rivenson A, Simi B et al: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res 55: 1464-1472, 1995
  pubmed

P.225 掲載の参考文献

• 1) Read TE, Read JD, Butterly LF: Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. N Engl JMed 336: 8-12, 1997
  pubmed

• 2) Winawer SJ, Zauber AG, 0'Brien MJ et al: Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl JMed 328: 901-906, 1993

P.227 掲載の参考文献

• 1) Klein KB: Controlled treatment trials in the irritable bowel syndrome: acritique. Gastroenterology 95: 232-241, 1988

P.229 掲載の参考文献

• 1) Tasman-Jones C: Mebeverine in patients with the irritable colon syndrome: double blind study. N Z Med J 77: 232-235, 1973
  pubmed

• 2) Inauen W, Halter F: Clinical efficacy, safety and tolerance of mebeverine slow release (200mg) versus mebeverine tablets in patients with irritable bowel syndrome. Drug lnvest 8: 234-240, 1994

• 3) Kruis W, Thieme C, Weinzierl M et al: A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 87: 1-7, 1984

P.231 掲載の参考文献

• 1) Maggi CA, Manzini S, Meli A: Octylonium bromide: a smooth muscle relaxant which interferes with calcium ions mobilization. Arch lnt Pharmacodyn 264: 305-323, 1983

• 2) Drossman DA, Thompson WG, Talley NJ et al: Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol lntl 3: 159-172, 1990

• 3) Klein KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 95: 232-241, 1988
  pubmed

P.233 掲載の参考文献

• 1) Young SJ, Alpers D H, Norland CC et al: Psychiatric illness and the irritable bowel syndrome. ；Practical implications for the primary physician. Gastroenterology 70: 162-166, 1976
  pubmed

• 2) Manning AP, Thompson WG, Heaton KW et al: Towards positive diagnosis of the irritable bowel. Br Med J 2 : 653-654, 1978
  pubmed

• 3) Mayer EA, Raybould HE: Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 99: 1688-1704, 1990
  pubmed

P.235 掲載の参考文献

• 1) Magni G: The use of antidepressants in the treatment of chronic pain. A review of the current article. Drugs 42: 730-748, 1991
  pubmed

• 2) Loldrup D, Langemark M, Hansen HJ et al: Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology 99: 1-7, 1989
  pubmed

P.237 掲載の参考文献

• 1) 正宗 研, 福富久之, 松尾 裕ほか: 過敏性腸症候群に対するポリカルボフィルカルシウム錠 (HSR-237) の後期第II相試験; 二重盲検法による用量検討試験. 薬理と治療 26(suppl 5): S945-S965, 1988

• 2) Saito T, Mizutani F, Iwanaga Y et al: Anti-diarrheal and anti-constipative effects of HSR-237, an agent for treating irritable bowel syndrome, in rats and mice. JJ Pharmacot 67(suppl 1): 203, 1995

• 3) 佐々木大輔, 吉田 豊, 棟方昭博ほか: 過敏性腸症候群に対するポリカルボフィルムカルシウム錠 (HSR-237) の臨床評価. 薬理と治療 26(suppl 5): S1045-S1059, 1998

P.239 掲載の参考文献

• 1) Takenaga H, Magaribuchi T, Tamaki H: Effects of trimebutine maleate (TM-906) on the spontaneous contraction of isolated guinea pig colon. JJ Pharmacol 34: 177-181, 1984

• 2) 長瀬 清, 斉藤雅雄, 高橋建二ほか: Trimebutine の消化器不定愁訴に対する臨床試験. 診療と新薬 19: 347-355, 1982

• 3) 佐々木大輔: 大腸運動に対する Trimebutine maleate (Cerekinon) の作用についての検討 Therapeutic Research 3: 788-796, 1985
  Medical*Online

P.241 掲載の参考文献

• 1) Kilpatrick GJ, Bunce KT, Tyers MB: 5-HT? receptors. Med Res Rev 10: 441-475, 1990
  pubmed

• 2) Costall B, Naylor RJ: 5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 8: 769-787, 1990
  pubmed

• 3) Maxton DG, Morris J, Whorwell PJ et al: Improving clinical trials in irritable bowel syndrome: some practical aspects. Eur J Gastroenterol Hepatol 4: 337-441, 199d2

P.243 掲載の参考文献

• 1) Klein KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 95: 232-241, 1988
  pubmed

• 2) Van Outryve M, Milo R, Toussaint J et al: “Prokinetic”treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 13: 49-57, 1991

P.245 掲載の参考文献

• 1) 板橋道朗: 大腸癌術後イレウスに対する大建中湯の有用性. 腸管機能研究会記録集-漢方と腸管機能, 日本医学館, 東京, 1997 pp9-16

• 2) 堀尾 静, 須田 賢, 村瀬正治ほか: 癒着性イレウス-特に再発性イレウスに対する漢方治療の効果-. Prog Med 12: 1663-1667, 1992

• 3) 大藪久則, 松田昌三, 栗栖 茂ほか: 癒着性イレウスに対するrandomized trialによる大建中湯の評価. Prog Med 15: 1954-1958, 1995